2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4179 Tenacity-01 a Global phase 1b/2 Study of CTD402, allogeneic anti-CD7 CAR T-cell, in relapsed/refractory, or minimal residual disease positive (MRD+) T-cell Acute Lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL)

Mark Blaine Geyer, MD, Nitin Jain, MD2, Kevin Curran, MD3, R. Alejandro Sica, MD4, Haydar Frangoul, MD, MS5, Hassan B Alkhateeb, M.D.6, Gregory W Roloff, MD7, Ming GAO8, Wengang GE9, Yajin Ni10, Cheryl Cai11, Raphael Chavanne12, Haley Irons, N/A13, Ben Capoccia, PhD14, Brett Ramsey15, Maria del Rosario16, Eileen McNulty17, Jiangtao Ren, PhD18, Jan Kenneth Davidson-Moncada, MSc, MD, PhD19, Lori Muffly, MD20
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 MD Anderson Cancer Center, Houston, Texas, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Montefiore Medical Center, Bronx, New York, United States
5 Sarah Cannon Research Institute, Nashville, Tennessee, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 University of Chicago, Chicago, Illinois, United States
8 Imviva Biotech, Boston, MA, United States
9 Imviva Biotech, Boston, MA, United States
10 Imviva Biotech, Boston, MA, United States
11 Imviva Biotech, Boston, MA, United States
12 Imviva Biotech, Boston, MA, United States
13 Imviva Biotech, Boston, MA, United States
14 Imviva Biotech, Boston, MA, United States
15 Imviva Biotech, Boston, MA, United States
16 Imviva Biotech, Boston, MA, United States
17 Imviva Biotech, Boston, MA, United States
18 Imviva Biotech, Boston, MA, United States
19 Imviva Biotech, Boston, MA, United States
20 Stanford University School of Medicine, Palo Alto, CA, United States

Introduction 

CAR-T cell therapy has transformed outcomes for patients with B-cell malignancies but its application to T-cell malignancies presents distinct challenges. In T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL), shared antigen expression between malignant and normal T-cells complicates autologous or in vivo CAR-T manufacturing due to limited availability of healthy T-cells, leukemic cell contamination, and the risk of transducing malignant cells. Allogeneic CAR-T strategies overcome these challenges but risk host-mediated immune rejection, impairing CAR-T expansion/persistence and reduce efficacy. Enhanced lymphodepletion (LD) to suppress CAR-T rejection risks cytopenias, infection, and treatment-related mortality. CTD402 is an allogeneic, CD7-targeted CAR-T product powered by ANSWER™ (ANSi5) anti-rejection platform technology to enable expansion/persistence using standard-dose LD. Clinical experience in China (>100 patients treated) has supported CTD402’s activity (Lu et al., Blood 2025). Herein we update results from the ongoing Phase 2 TENACITY-01 Study. 

Methods 

TENACITY-01 (NCT#07070219) is a global Phase 1b/2 study of CTD402 in patients ≥1 years with R/R T-ALL/LBL. Eligible patients receive standard LD with fludarabine 30 mg/m²/day and cyclophosphamide 500 mg/m²/day on Days −5 to −3, followed by a single infusion of CTD402 at the recommended Phase 2 dose (RP2D) of 400 × 10⁶ CAR-T⁺ cells on Day 0. Primary objectives are safety and efficacy, defined by composite complete remission rate (CRc: CR/CRi) and overall response rate (ORR: CRc + PR) (Maude et al., NEJM. 2018).  

Results 

As of July 10th, 2026, 9 patients with R/R T-ALL/LBL have been evaluated at RP2D in TENACITY-01. Patients were heavily pre-treated (median 4 lines of therapy; range 1-9), median age 29 years (range 13-56), 3/9 (33.3%) with prior allo-HSCT, median baseline bone marrow blasts 52% (range 11% - 90%), and 8/9 (88.9%) with extramedullary disease.  

CTD402 demonstrated a manageable safety profile. CRS occurred in 8 patients (88.9%) and mostly low grade (G1 63%) with one G3 event reported lasting <24 hours. Immune effector cell-associated hemophagocytic syndrome (IEC-HS) was observed in 2 patients at G1 & G2 as transient lab abnormalities, e.g., ferritinemia, and managed conservatively. 

Notably, no ICANS or GvHD were reported. Grade ≥3 treatment-related adverse events included febrile neutropenia (22.2%), decreased blood fibrinogen (22.2%), and single events of non-infectious diarrhea, transaminase elevations, and neutropenia occurring (11.1%). Grade ≥3 infections occurred in 4 patients; one patient with concurrent G3 pneumonia and G4 sepsis. Most events were unrelated to CTD402 and occurred between Days 34-42. One treatment related event of Grade 2 gram-positive cocci on Day 13 was considered possibly related to CTD402; CAR-T related immunosuppression may have contributed to central line infection, cleared in 6 days with broad-spectrum antibiotics. No treatment related deaths have been reported.  

Among 5 subjects with available PK data, CTD402 had robust expansion and persistence in peripheral blood following standard-dose LD. Peak expansion occurred at Day 10-14 with a median cMax of 445,694 copies/μg DNA and median AUC of 3,356,088 (copies/µg DNA). Persistence > 28 days was observed in 80% (4/5) of patients. Importantly, CTD402 was also detected at significant levels in 75% (3/4) of patients in Day 28 bone marrow samples, showing CAR-T penetration at the disease site. CTD402 demonstrated robust anti-leukemic activity with an ORR of 77.8% (7/9) and a CRc of 66.7% (6/9). All patients achieving CRc were MRD-negative (6/6). With a short duration of follow up (median 4.43 months; range 1-NR), the median duration of response has not been reached. At the data cut, four patients received allo-HSCT with complete engraftment at a median of 16 days post HSCT (range 14-20).  

Conclusions 

CTD402 is a universally applicable, allogeneic anti-CD7 CAR-T enabling robust expansion and persistence with standard-dose LD. Early data from the global TENACITY-01 study reflect an acceptable safety profile, suggest early clinical activity in heavily pre-treated patients, and support CTD402’s continued development as an accessible, point-of-care therapy for this patient population with high unmet needs. Enrollment in Phase 2 of TENACITY-01 is ongoing. 

Mark Blaine Geyer, MD: Actinium Pharmaceuticals, Inc. - Research Funding; Amgen - Research Funding; Amgen - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)